According to reports from Business Standard, Windlas Biotech reported a marginal decline in standalone net profit for the quarter ended June 2026. The company's net profit decreased by 0.11% to ₹17.65 crore compared to ₹17.67 crore in the corresponding quarter of the previous year. Despite the slight profit decline, the company demonstrated strong revenue growth during the quarter. The company's revenue reached ₹248.10 crore compared to ₹210.09 crore in the same quarter of the previous year, representing an 18.09% increase in sales.
As reported by Business Standard, Windlas Biotech achieved robust revenue growth during the June 2026 quarter. Sales rose by 18.09% to ₹248.10 crore compared to ₹210.09 crore in the same quarter of the previous year. This significant revenue increase indicates strong business performance and market demand for the company's products and services. The company's TTM revenue stands at ₹904 crore with operating profit of ₹105 crore and operating profit margin of 11%.
According to the financial data reported by Business Standard, the company's operating profit margin (OPM) declined to 10.75% in the June 2026 quarter from 12.63% in the corresponding quarter of the previous year. Additionally, PBDT decreased by 2% to ₹30.14 crore from ₹30.71 crore, while PBT fell by 1% to ₹22.93 crore from ₹23.26 crore in the year-ago period. These operational metrics suggest some margin pressure despite the strong revenue growth. The company's working capital requirements have improved significantly, reducing from 21.4 days to 14.4 days.
As reported by Business Standard, the financial results were announced on August 10, 2026, with the company's performance being covered in the capital market news section. The marginal profit decline alongside strong revenue growth indicates mixed operational performance during the quarter, with the company maintaining its focus on revenue expansion while facing some margin challenges. The company has also completed a ₹47 crore buyback and promoter holding has increased by 1.41% over the last quarter. The company maintains a healthy dividend payout of 19.8% and is among the top five players in the domestic pharmaceutical formulations CDMO industry in India.
